---
title: "Epilepsy"
order: 2
category: "Neurology"
---

# Epilepsy

## Overview

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures due to abnormal electrical activity in the brain. It affects approximately 1% of the population worldwide and represents one of the most common serious neurological conditions. Epilepsy can significantly impact quality of life, but with appropriate treatment, most patients can achieve seizure control.

### Definition and Classification
- **Seizure**: Transient episode of abnormal excessive neuronal activity
- **Epilepsy**: Tendency for recurrent unprovoked seizures (≥2 seizures >24 hours apart)
- **Unprovoked**: Not due to acute precipitating cause
- **Provoked**: Secondary to acute brain insult or systemic condition

## Classification of Seizures

### 2017 ILAE Classification

#### Focal Seizures (Partial)
- **Origin**: Localized brain networks
- **Consciousness**: May be preserved or impaired
- **Subtypes**: Focal aware, focal impaired awareness
- **Evolution**: May progress to bilateral tonic-clonic

##### Focal Aware Seizures
- **Consciousness**: Preserved throughout seizure
- **Symptoms**: Motor, sensory, autonomic, psychic phenomena
- **Duration**: Usually <2 minutes
- **Examples**: Simple partial motor, sensory auras

##### Focal Impaired Awareness Seizures
- **Consciousness**: Altered or impaired during seizure
- **Behavior**: Automatisms, confusion, unresponsiveness
- **Duration**: 1-3 minutes typically
- **Post-ictal**: Confusion, fatigue common

#### Generalized Seizures
- **Origin**: Bilateral brain networks from onset
- **Consciousness**: Always impaired (except some myoclonic)
- **Types**: Tonic-clonic, absence, myoclonic, atonic, tonic, clonic

##### Generalized Tonic-Clonic Seizures
- **Phases**: Tonic (stiffening) → clonic (jerking)
- **Duration**: 1-3 minutes typically
- **Features**: Loss of consciousness, tongue biting, incontinence
- **Post-ictal**: Confusion, fatigue, muscle soreness

##### Absence Seizures
- **Consciousness**: Brief impairment (5-30 seconds)
- **Behavior**: Staring, minimal motor activity
- **EEG**: 3 Hz spike-and-wave complexes
- **Types**: Typical vs atypical

##### Myoclonic Seizures
- **Characteristics**: Brief, shock-like muscle jerks
- **Duration**: <1 second
- **Consciousness**: Usually preserved
- **Distribution**: Single muscle or muscle groups

##### Atonic Seizures (Drop Attacks)
- **Characteristics**: Sudden loss of muscle tone
- **Fall risk**: High injury potential
- **Duration**: 1-3 seconds typically
- **Associated**: Often with intellectual disability

#### Unknown Onset Seizures
- **Classification**: Inadequate information about onset
- **Reclassification**: May be reclassified with more information
- **Types**: Tonic-clonic, epileptic spasms

## Epilepsy Syndromes

### Idiopathic Generalized Epilepsies

#### Childhood Absence Epilepsy
- **Age of onset**: 4-8 years
- **Seizures**: Typical absence seizures
- **EEG**: 3 Hz spike-and-wave
- **Prognosis**: Good, often remits in adolescence
- **Treatment**: Ethosuximide, valproic acid

#### Juvenile Myoclonic Epilepsy
- **Age of onset**: Adolescence (12-18 years)
- **Seizures**: Myoclonic, tonic-clonic, sometimes absence
- **Triggers**: Sleep deprivation, alcohol, stress
- **Prognosis**: Lifelong condition, good seizure control possible
- **Treatment**: Valproic acid, levetiracetam

#### Juvenile Absence Epilepsy
- **Age of onset**: 10-17 years
- **Seizures**: Absence seizures, often with tonic-clonic
- **Frequency**: Less frequent than childhood absence
- **Prognosis**: Usually requires lifelong treatment

### Focal Epilepsies

#### Temporal Lobe Epilepsy
- **Most common**: Adult focal epilepsy syndrome
- **Subtypes**: Mesial vs lateral temporal
- **Seizures**: Focal impaired awareness with automatisms
- **Pathology**: Hippocampal sclerosis common
- **Surgery**: May be surgical candidate if drug-resistant

#### Frontal Lobe Epilepsy
- **Characteristics**: Nocturnal seizures, brief duration
- **Semiology**: Motor manifestations, posturing
- **Clusters**: Often occur in clusters
- **Diagnosis**: May be difficult to distinguish from sleep disorders

### Developmental and Epileptic Encephalopathies

#### West Syndrome (Infantile Spasms)
- **Age of onset**: 3-12 months
- **Seizures**: Epileptic spasms in clusters
- **EEG**: Hypsarrhythmia
- **Development**: Developmental regression
- **Treatment**: ACTH, vigabatrin, prednisolone

#### Lennox-Gastaut Syndrome
- **Age of onset**: 3-5 years
- **Seizures**: Multiple types (tonic, atonic, absence, tonic-clonic)
- **EEG**: Slow spike-and-wave complexes
- **Prognosis**: Poor, significant intellectual disability
- **Treatment**: Valproic acid, lamotrigine, rufinamide

#### Dravet Syndrome
- **Age of onset**: First year of life
- **Genetics**: SCN1A mutations (80%)
- **Seizures**: Febrile and afebrile seizures, multiple types
- **Development**: Normal early, then regression
- **Treatment**: Stiripentol, clobazam, valproic acid

## Pathophysiology

### Normal Brain Function
- **Excitation-inhibition balance**: GABA (inhibitory) vs glutamate (excitatory)
- **Neuronal networks**: Coordinated activity patterns
- **Synchronization**: Normal vs pathological synchrony
- **Plasticity**: Activity-dependent changes in connectivity

### Seizure Generation

#### Cellular Mechanisms
- **Membrane instability**: Altered ion channel function
- **Neurotransmitter imbalance**: Increased excitation or decreased inhibition
- **Metabolic factors**: Energy failure, pH changes
- **Structural abnormalities**: Altered connectivity, cell loss

#### Network Mechanisms
- **Hypersynchronization**: Abnormal neuronal synchrony
- **Propagation**: Spread through anatomical connections
- **Recruitment**: Progressive involvement of brain regions
- **Termination**: Inhibitory mechanisms, energy depletion

### Molecular Basis

#### Ion Channel Mutations
- **Sodium channels**: SCN1A, SCN2A (Dravet syndrome, BFNC)
- **Potassium channels**: KCNQ2, KCNQ3 (BFNC)
- **Calcium channels**: CACNA1A (episodic ataxia, hemiplegic migraine)
- **Chloride channels**: CLCN2 (IGE)

#### Neurotransmitter Systems
- **GABA receptors**: GABRG2, GABRA1 (generalized epilepsies)
- **Glycine receptors**: GLRA1, GLRB
- **Nicotinic receptors**: CHRNA4, CHRNB2 (ADNFLE)

#### Metabolic Pathways
- **Glucose transport**: GLUT1 deficiency syndrome
- **Energy metabolism**: Mitochondrial disorders
- **Amino acid metabolism**: Pyridoxine-dependent epilepsy

## Etiology

### Genetic Causes
- **Single gene mutations**: Ion channels, neurotransmitter receptors
- **Chromosomal abnormalities**: Deletions, duplications
- **Complex inheritance**: Multiple genes, environmental factors
- **De novo mutations**: New mutations in affected individual

### Structural Causes

#### Developmental Malformations
- **Cortical dysplasia**: Abnormal cortical development
- **Heterotopia**: Misplaced neurons
- **Polymicrogyria**: Excessive small gyri
- **Schizencephaly**: Clefts in cerebral hemispheres

#### Acquired Lesions
- **Hippocampal sclerosis**: Mesial temporal sclerosis
- **Tumors**: Primary or metastatic brain tumors
- **Vascular malformations**: AVMs, cavernomas
- **Traumatic brain injury**: Penetrating or closed head injury
- **Infections**: Encephalitis, brain abscess, parasitic infections
- **Stroke**: Ischemic or hemorrhagic cerebrovascular disease

### Metabolic Causes
- **Electrolyte abnormalities**: Hyponatremia, hypocalcemia, hypomagnesemia
- **Glucose disorders**: Hypoglycemia, hyperglycemia
- **Inherited metabolic disorders**: Amino acid, organic acid disorders
- **Mitochondrial disorders**: Respiratory chain defects

### Infectious Causes
- **Acute infections**: Meningitis, encephalitis
- **Chronic infections**: Tuberculosis, fungal infections
- **Parasitic infections**: Neurocysticercosis, toxoplasmosis
- **Autoimmune encephalitis**: Anti-NMDA receptor, LGI1, CASPR2

### Unknown Causes
- **Cryptogenic**: Presumed symptomatic but cause unknown
- **Idiopathic**: No underlying cause identified
- **Proportion**: 30-40% of epilepsies remain unexplained

## Clinical Presentation

### Seizure Semiology

#### Motor Manifestations
- **Tonic**: Sustained muscle contraction
- **Clonic**: Rhythmic jerking movements
- **Myoclonic**: Brief, shock-like jerks
- **Atonic**: Sudden loss of muscle tone
- **Automatisms**: Complex, repetitive behaviors

#### Non-Motor Manifestations
- **Sensory**: Visual, auditory, somatosensory phenomena
- **Autonomic**: Changes in heart rate, blood pressure, breathing
- **Psychic**: Fear, déjà vu, jamais vu, forced thinking
- **Cognitive**: Speech arrest, confusion, memory impairment

### Auras
- **Definition**: Focal aware seizures, subjective symptoms
- **Types**: Sensory, psychic, autonomic, motor
- **Localization**: May provide clues to seizure focus
- **Warning**: May allow patient to prepare for seizure

### Post-Ictal State
- **Duration**: Minutes to hours after seizure
- **Symptoms**: Confusion, fatigue, headache, muscle soreness
- **Todd's paralysis**: Temporary weakness after focal motor seizure
- **Recovery**: Gradual return to baseline function

### Status Epilepticus
- **Definition**: Continuous seizure activity >5 minutes or recurrent seizures without recovery
- **Types**: Convulsive vs non-convulsive
- **Medical emergency**: Risk of permanent brain damage
- **Mortality**: 10-20% depending on etiology and duration

## Diagnosis

### Clinical History

#### Seizure Description
- **Witness account**: Detailed description from observer
- **Patient experience**: Aura, awareness, memory
- **Timeline**: Onset, progression, duration, recovery
- **Triggers**: Sleep deprivation, stress, alcohol, specific stimuli
- **Frequency**: Pattern and clustering of seizures

#### Medical History
- **Birth history**: Perinatal complications
- **Developmental milestones**: Normal vs delayed
- **Head trauma**: Significant injuries
- **Previous seizures**: Febrile seizures, provoked seizures
- **Family history**: Epilepsy, febrile seizures, genetic disorders
- **Medications**: Current and past antiseizure drugs

### Physical Examination
- **General**: Signs of genetic syndromes, developmental disorders
- **Neurological**: Focal deficits, cognitive assessment
- **Skin**: Neurocutaneous stigmata (café-au-lait spots, ash leaf spots)
- **Post-ictal**: Tongue biting, incontinence, injuries

### Electroencephalography (EEG)

#### Routine EEG
- **Duration**: 20-30 minutes recording
- **Indications**: Initial evaluation of suspected epilepsy
- **Yield**: 50% show epileptiform activity in first EEG
- **Limitations**: Brief recording, may miss abnormalities

#### Sleep-Deprived EEG
- **Activation**: Sleep deprivation increases yield
- **Procedure**: 24-hour sleep deprivation before recording
- **Yield**: Higher than routine EEG
- **Sleep recording**: Natural sleep during EEG

#### Prolonged EEG Monitoring
- **Video-EEG**: Continuous monitoring with video
- **Duration**: 1-7 days typically
- **Indications**: Seizure characterization, pre-surgical evaluation
- **Yield**: Very high for capturing seizures

#### Ambulatory EEG
- **Setting**: Outpatient monitoring
- **Duration**: 24-72 hours
- **Advantages**: Natural environment, cost-effective
- **Limitations**: No video correlation

### Neuroimaging

#### Magnetic Resonance Imaging (MRI)
- **Standard**: Should be performed in most patients
- **Protocol**: Epilepsy-specific sequences
- **Findings**: Structural abnormalities, hippocampal sclerosis
- **Timing**: May need to repeat if initially normal

#### Computed Tomography (CT)
- **Emergency**: Acute setting, status epilepticus
- **Limitations**: Poor visualization of temporal lobes
- **Indications**: Contraindications to MRI, emergency

#### Functional Imaging
- **PET**: Glucose metabolism, neurotransmitter function
- **SPECT**: Cerebral blood flow patterns
- **Indications**: Pre-surgical evaluation, research
- **Findings**: Hypometabolism (interictal), hypermetabolism (ictal)

### Laboratory Studies

#### Routine Studies
- **Complete blood count**: Baseline for drug monitoring
- **Comprehensive metabolic panel**: Electrolytes, glucose, liver function
- **Antiseizure drug levels**: Therapeutic monitoring

#### Specialized Studies
- **Genetic testing**: Suspected genetic epilepsy syndrome
- **Metabolic studies**: Amino acids, organic acids
- **Autoimmune studies**: Suspected autoimmune encephalitis
- **CSF analysis**: If infection or inflammation suspected

### Differential Diagnosis

#### Syncope
- **Mechanism**: Transient global cerebral hypoperfusion
- **Triggers**: Standing, emotional stress, pain
- **Prodrome**: Lightheadedness, nausea, diaphoresis
- **Recovery**: Rapid, oriented immediately

#### Psychogenic Non-Epileptic Seizures (PNES)
- **Prevalence**: 20-30% of patients in epilepsy monitoring units
- **Characteristics**: Variable semiology, emotional triggers
- **Diagnosis**: Video-EEG monitoring
- **Treatment**: Psychological intervention

#### Movement Disorders
- **Paroxysmal dyskinesias**: Brief episodes of involuntary movements
- **Tics**: Repetitive, stereotyped movements
- **Tremor**: Rhythmic oscillations
- **Myoclonus**: Brief, shock-like jerks

#### Sleep Disorders
- **Night terrors**: Partial arousal from slow-wave sleep
- **REM behavior disorder**: Acting out dreams
- **Periodic limb movements**: Repetitive leg movements
- **Sleep talking**: Vocalizations during sleep

#### Migraine
- **Basilar migraine**: May mimic seizures
- **Visual aura**: Fortification spectra
- **Duration**: Usually longer than seizures
- **Recovery**: Gradual vs rapid

## Treatment

### Antiseizure Medications (ASMs)

#### First-Generation ASMs

##### Phenytoin
- **Mechanism**: Sodium channel blocker
- **Indications**: Focal seizures, generalized tonic-clonic
- **Dosing**: 300-400 mg daily, nonlinear kinetics
- **Side effects**: Gingival hyperplasia, hirsutism, osteoporosis
- **Monitoring**: Drug levels, complete blood count

##### Carbamazepine
- **Mechanism**: Sodium channel blocker
- **Indications**: Focal seizures, trigeminal neuralgia
- **Dosing**: 400-1200 mg daily
- **Side effects**: Diplopia, ataxia, hyponatremia
- **Contraindications**: Absence seizures, myoclonic seizures

##### Valproic Acid
- **Mechanism**: Multiple (GABA, T-type calcium channels)
- **Indications**: Generalized epilepsies, broad spectrum
- **Dosing**: 750-3000 mg daily
- **Side effects**: Weight gain, hair loss, tremor, hepatotoxicity
- **Teratogenicity**: High risk, avoid in pregnancy

##### Ethosuximide
- **Mechanism**: T-type calcium channel blocker
- **Indications**: Absence seizures (drug of choice)
- **Dosing**: 500-1500 mg daily
- **Side effects**: GI upset, headache, dizziness
- **Monitoring**: Drug levels, complete blood count

#### Second-Generation ASMs

##### Lamotrigine
- **Mechanism**: Sodium channel blocker, glutamate release inhibition
- **Indications**: Broad spectrum, good tolerability
- **Dosing**: 100-400 mg daily, slow titration
- **Side effects**: Rash (especially with valproate), diplopia
- **Drug interactions**: Affected by enzyme inducers/inhibitors

##### Levetiracetam
- **Mechanism**: SV2A protein binding
- **Indications**: Broad spectrum, minimal drug interactions
- **Dosing**: 1000-3000 mg daily
- **Side effects**: Behavioral changes, somnolence
- **Advantages**: Rapid titration, renal elimination

##### Oxcarbazepine
- **Mechanism**: Sodium channel blocker (carbamazepine analog)
- **Indications**: Focal seizures, better tolerated than carbamazepine
- **Dosing**: 900-2400 mg daily
- **Side effects**: Hyponatremia, diplopia, dizziness
- **Advantages**: Less drug interactions than carbamazepine

##### Topiramate
- **Mechanism**: Multiple (sodium channels, GABA, glutamate)
- **Indications**: Focal and generalized seizures, migraine prevention
- **Dosing**: 200-400 mg daily
- **Side effects**: Cognitive impairment, weight loss, kidney stones
- **Contraindications**: Metabolic acidosis, acute angle-closure glaucoma

#### Third-Generation ASMs

##### Lacosamide
- **Mechanism**: Slow sodium channel inactivation enhancement
- **Indications**: Focal seizures, adjunctive therapy
- **Dosing**: 200-400 mg daily
- **Side effects**: Dizziness, diplopia, nausea
- **Advantages**: Minimal drug interactions

##### Perampanel
- **Mechanism**: AMPA receptor antagonist
- **Indications**: Focal seizures, generalized tonic-clonic
- **Dosing**: 4-12 mg daily
- **Side effects**: Behavioral changes, dizziness, somnolence
- **Warnings**: Serious behavioral adverse effects

### Treatment Principles

#### Monotherapy vs Polytherapy
- **First-line**: Monotherapy preferred initially
- **Drug selection**: Based on seizure type, syndrome, patient factors
- **Failure**: Try alternative monotherapy before polytherapy
- **Polytherapy**: Rational combinations, complementary mechanisms

#### Dosing and Titration
- **Start low**: Minimize acute side effects
- **Titrate slowly**: Allow time for adaptation
- **Therapeutic levels**: Aim for seizure control, not specific levels
- **Maximum tolerated dose**: Balance efficacy and tolerability

#### Therapeutic Drug Monitoring
- **Indications**: Poor seizure control, suspected toxicity, drug interactions
- **Interpretation**: Correlation with clinical response
- **Free levels**: Consider in pregnancy, hypoalbuminemia
- **Timing**: Steady state (5 half-lives)

### Drug-Resistant Epilepsy

#### Definition
- **ILAE definition**: Failure of adequate trials of 2 tolerated, appropriately chosen ASMs
- **Prevalence**: 30-40% of patients with epilepsy
- **Impact**: Increased morbidity, mortality, healthcare costs
- **Evaluation**: Reconsider diagnosis, optimize treatment

#### Alternative Treatments

##### Epilepsy Surgery
- **Candidates**: Drug-resistant focal epilepsy with identified focus
- **Evaluation**: Comprehensive presurgical assessment
- **Procedures**: Resection, disconnection, ablation
- **Outcomes**: 60-70% seizure-free at 2 years

##### Vagus Nerve Stimulation (VNS)
- **Indications**: Drug-resistant epilepsy, not surgical candidate
- **Mechanism**: Intermittent electrical stimulation of vagus nerve
- **Outcomes**: 50% reduction in seizures in 30-40% of patients
- **Side effects**: Voice changes, cough, throat discomfort

##### Responsive Neurostimulation (RNS)
- **Indications**: Drug-resistant epilepsy with 1-2 seizure foci
- **Mechanism**: Responsive electrical stimulation
- **Outcomes**: Median 50% seizure reduction
- **Complications**: Infection, bleeding, device malfunction

##### Deep Brain Stimulation (DBS)
- **Target**: Anterior nucleus of thalamus
- **Indications**: Drug-resistant focal epilepsy
- **Outcomes**: Median 40-50% seizure reduction
- **Consideration**: Investigational for other targets

##### Ketogenic Diet
- **Mechanism**: Metabolic changes, ketone bodies
- **Indications**: Drug-resistant epilepsy, especially children
- **Efficacy**: 50% reduction in seizures in 30-40% of patients
- **Side effects**: Kidney stones, growth retardation, hyperlipidemia

## Special Situations

### Women with Epilepsy

#### Pregnancy
- **Preconception counseling**: Folate supplementation, ASM optimization
- **Teratogenicity**: Valproate highest risk, lamotrigine/levetiracetam lower risk
- **Pharmacokinetics**: Drug levels may decrease due to physiological changes
- **Monitoring**: Regular drug levels, fetal monitoring

#### Contraception
- **Drug interactions**: Enzyme-inducing ASMs reduce hormonal contraceptive efficacy
- **Options**: Higher dose hormonal contraceptives, non-hormonal methods
- **Counseling**: Discuss interactions and pregnancy planning

### Status Epilepticus

#### First-Line Treatment
- **Benzodiazepines**: Lorazepam 0.1 mg/kg IV, diazepam, midazolam
- **Timing**: Should be given within 5 minutes
- **Efficacy**: Terminates seizures in 60-80% of cases
- **Side effects**: Respiratory depression, sedation

#### Second-Line Treatment
- **Antiseizure drugs**: Phenytoin, valproate, levetiracetam
- **Dosing**: Loading doses required
- **Timing**: If seizures continue after benzodiazepines
- **Monitoring**: Cardiac rhythm, blood pressure

#### Refractory Status Epilepticus
- **Definition**: Continues despite adequate first and second-line treatment
- **Treatment**: Continuous infusions (midazolam, propofol, pentobarbital)
- **Monitoring**: Continuous EEG, intensive care
- **Complications**: Hypotension, respiratory failure

### Elderly Patients
- **Etiology**: Often symptomatic (stroke, dementia, tumors)
- **Drug selection**: Consider drug interactions, comorbidities
- **Dosing**: Lower starting doses, slower titration
- **Monitoring**: Increased risk of side effects

## Complications

### Seizure-Related Injuries
- **Head trauma**: Falls during seizures
- **Burns**: Contact with hot objects
- **Fractures**: Compression fractures, shoulder dislocations
- **Drowning**: Seizures in water
- **Motor vehicle accidents**: Driving restrictions

### Cognitive and Behavioral Effects
- **Memory impairment**: Especially temporal lobe epilepsy
- **Attention deficits**: Subtle cognitive dysfunction
- **Mood disorders**: Depression, anxiety common
- **Psychosis**: Especially in temporal lobe epilepsy

### Social and Economic Impact
- **Employment**: Discrimination, job limitations
- **Education**: Learning difficulties, missed school
- **Driving**: License restrictions vary by jurisdiction
- **Insurance**: Health, life, disability insurance issues
- **Stigma**: Social isolation, reduced quality of life

### Sudden Unexpected Death in Epilepsy (SUDEP)
- **Incidence**: 1-2 per 1000 patient-years
- **Risk factors**: Drug-resistant epilepsy, generalized tonic-clonic seizures
- **Mechanism**: Unclear, possibly respiratory/cardiac
- **Prevention**: Optimal seizure control, supervision

## Prognosis

### Seizure Control
- **Overall**: 60-70% achieve seizure freedom with ASMs
- **Remission**: 2-5 year seizure-free periods in 60-80%
- **Drug resistance**: 30-40% remain drug-resistant
- **Surgery**: Additional 60-70% seizure-free rate in appropriate candidates

### Factors Affecting Prognosis

#### Favorable Factors
- **Idiopathic epilepsy**: Better prognosis than symptomatic
- **Single seizure type**: Easier to control
- **Normal development**: Better cognitive outcomes
- **Early seizure control**: Predicts long-term remission

#### Unfavorable Factors
- **Early onset**: Especially first year of life
- **Frequent seizures**: Multiple seizures before treatment
- **Multiple seizure types**: Harder to control
- **Developmental delay**: Associated with worse outcomes
- **Abnormal EEG**: Persistent abnormalities

### Quality of Life
- **Seizure frequency**: Most important factor
- **ASM side effects**: Can significantly impact quality of life
- **Psychosocial factors**: Depression, anxiety, social support
- **Functional status**: Independence in activities of daily living

### Mortality
- **Overall**: 2-3 times higher than general population
- **SUDEP**: Leading cause of death in drug-resistant epilepsy
- **Accidents**: Seizure-related injuries
- **Underlying condition**: Brain tumors, progressive disorders
- **Status epilepticus**: 10-20% mortality rate

## Prevention

### Primary Prevention
- **Head injury prevention**: Helmet use, safety measures
- **Stroke prevention**: Vascular risk factor management
- **Infection prevention**: Vaccination, prompt treatment
- **Prenatal care**: Prevention of birth complications

### Secondary Prevention
- **Seizure triggers**: Identify and avoid triggers
- **Medication adherence**: Critical for seizure control
- **Lifestyle modifications**: Adequate sleep, stress management
- **Regular follow-up**: Monitor for breakthrough seizures

### Genetic Counseling
- **Family planning**: Risk assessment for inherited epilepsies
- **Genetic testing**: When indicated by syndrome or family history
- **Counseling**: Recurrence risks, testing options
- **Support**: Psychological support for families

## Key Points

- Epilepsy is defined by recurrent unprovoked seizures and affects 1% of the population
- Seizure classification (focal vs generalized) guides treatment decisions
- EEG and MRI are essential diagnostic tools, but clinical history remains paramount
- Most patients (60-70%) achieve seizure control with antiseizure medications
- Drug selection should be individualized based on seizure type, syndrome, and patient factors
- Drug-resistant epilepsy affects 30-40% of patients and requires alternative treatments
- Epilepsy surgery can provide seizure freedom in selected patients with drug-resistant focal epilepsy
- Special considerations apply to women of childbearing age, elderly patients, and emergency situations
- SUDEP is a serious complication that emphasizes the importance of optimal seizure control
- Comprehensive care addresses not only seizures but also psychosocial aspects of epilepsy

## References

1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia. 2017;58:522-530.
2. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069-1077.
3. Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551-563.